Clinical practice guideline for #NephJC?
What do people think about this? Is this appropriate for journal club or is this akin to doing a review article?
This week, we will discuss the origins of primary hyperaldosteronism in normotensive patients. Could this undetected anomaly be the cause of idiopathic hypertension and CKD?
This week, we will discuss the HOPE trial - no not that one - the one in dialysis that was a LBCT in 2024. Should we look beyond analgesics to non-pharmacological options more seriously?
Should we call 2024 the Renaissance of nephrology? It was probably the richest year in RCTs in the nephrology world, reflected in the higher number of Late-Breaking Clinical Trials sessions at every big nephrology congress. Probably 1st place won’t surprise anyone; it was the anticipated FLOW of the year, but this Top 10 Nephrology Stories definitely includes some unexpected titles
This week we come to meta-analyse, strikingly late, the cornerstone of all CKD treatments. Are you still in doubt? We need ACEing CKD to the end of GFR, and beyond
Why does the CKD screening matters? Because of this: http://t.co/HKuUTJgZvR @NephJC #nephJC
— Xavier F. Vela (@xaviervel) May 6, 2014
Though not a tradition subject for journal club, it seems that clinical practice guidelines have an important role in today’s practice (1/2)
— Joel Topf (@kidney_boy) May 5, 2014
I propose the new hyponatremia guidelines for #NephJC http://t.co/hNGxibmNfy (2/2)
— Joel Topf (@kidney_boy) May 5, 2014
What do people think about this? Is this appropriate for journal club or is this akin to doing a review article?
Chronic kidney disease blast Central America: http://t.co/7Yxkf8uMfb #renalweek #kidneyweek #NephJC pic.twitter.com/4XyXCbkzma
— Xavier F. Vela (@xaviervel) May 1, 2014
Latest hope for DN: endothelin antagonists http://t.co/64hQ0rs5xX one for #NephJC? @NephJC @kidney_boy
— Paul Phelan (@paulphel) April 23, 2014
http://t.co/siLrMR1v7i Time for routine kidney biopsy in all patients (not just the risk ones) with suspected GN? Paper for #NephJC ?
— ChristosArgyropoulos (@ChristosArgyrop) April 23, 2014
Prenatal risk factors for childhood CKD in JASN -- a possible peg article for #NephJC? http://t.co/t7hmG91XXS
— NatureRevNephrology (@NatRevNeph) April 25, 2014
Atrasentan lowers residual albuminuria T2DM, but ... "manageable" fluid-overload. #NephJC #CJASN http://t.co/G5C6FT5PSu
— Ernesto LopezAlmaraz (@kidney_doctor) April 29, 2014